Radiation therapy developer Accuray is highlighting research being presented at the International Stereotactic Radiosurgery Society (ISRS) meeting in Milan, Italy, that the company says demonstrates the value of its CyberKnife system for treating neurological indications.
Nearly 50 abstracts are being presented at ISRS 2022 on the company's technology. Accuray says that data being presented indicate that CyberKnife can deliver treatment to patients in as few as one to five sessions.
Research being presented at the meeting include studies on treating perioptic meningiomas, as well as patients who have previously received radiation treatment for recurrent primary brain tumors and metastases and who have limited treatment options left. Other studies address treatments for patients with craniopharyngioma, a slow-growing brain tumor, and CyberKnife can provide clinicians with a single fraction or ablative option for postoperative treatment of brain metastases.
